

IN THE CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising:  
a biocompatible carrier for injection or infusion, and an isolated and purified N-terminal  
fragment of ~~agglutinin~~ ~~agglutinin~~ like sequences (ALS1) cell surface adhesion protein (SEQ ID  
No. 7) obtained from *Candida albicans*, wherein the composition produces an effective immune  
response in a patient.

2. (Cancelled)

3. (Previously Presented) The composition of Claim 1, wherein the protein  
contains an adhesion binding site of *Candida albicans*.

4 - 8. (Cancelled)

9. (Currently Amended) The composition of claim 1 wherein the N terminal  
fragment of ALS1 protein is encoded by nucleotides 52 to 1296 of the nucleotide sequence of  
SEQ ID No. 7.

10. (Currently Amended) A pharmaceutical composition consisting essentially of:  
a biocompatible carrier for injection or infusion, and an isolated and purified N-  
terminal fragment of ~~agglutinin~~ ~~agglutinin~~ like sequences (ALS1) cell surface adhesion protein  
obtained from *Candida albicans*, wherein the composition produces an effective immune  
response in a patient.

11. (Previously Presented) The composition of Claim 1, wherein the protein contains an adhesion binding site of *Candida albicans*.

12. (Currently Amended) The composition of claim 1 wherein the N terminal fragment of ALS1 protein is encoded by nucleotides 52 to 1296 of SEQ ID No. 7.